Why is Cohance Life falling/rising?

As of 10-Nov, Cohance Lifesciences Ltd is experiencing a decline in its stock price, currently at 704.20, reflecting a decrease of 3.3 or 0.47%. The stock has hit a new 52-week low of Rs.700.15 today and has been on a downward trend, losing value for the last eight consecutive days, resulting in a total decline of 17.59% during this period. Additionally, the stock has underperformed its sector by 1.52%. Over the past week, it has seen a significant drop of 5.23%, and its year-to-date performance shows a staggering decline of 37.87%. The company has a high management efficiency with a return on equity (ROE) of 24.14% and a low debt-to-equity ratio, but these positive factors are overshadowed by poor long-term growth, as indicated by a mere 2.95% annual growth rate in operating profit over the last five years. Furthermore, the stock is trading at a premium compared to its peers, and 100% of promoter shares are pledged, which adds downward pressure in a falling market. In the broader market context, while the Sensex has shown a slight increase of 1.25% over the past month, Cohance Lifesciences Ltd has significantly underperformed, with a monthly decline of 22.17%. This stark contrast highlights the stock's struggles relative to the market. The overall market has generated positive returns of 3.81% over the past year, while Cohance has faced a dramatic decline of 44.77%. The falling investor participation, with a delivery volume that has decreased by 78.76% against the five-day average, further indicates a lack of confidence among investors, contributing to the stock's downward trajectory.